KALA BIO, Inc. (KALA) stock
KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.14−0.02 (-13.79%)
Close on Nov 13, 2026Market cap $2.68MP/E –Yield –
Kala Bio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Kala Bio's ebitda for the twelve months ending Dec 31, 2025 was -$38.84M. For fiscal 2025 it was -$38.84M. The highest annual figure on record is -$38.84M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$38.84M | – |
| FY2024 | Dec 31, 2024 | -$40.72M | – |
| FY2023 | Dec 31, 2023 | -$39.36M | – |
| FY2022 | Dec 31, 2022 | -$81.17M | – |
| FY2021 | Dec 31, 2021 | -$129.27M | – |
| FY2020 | Dec 31, 2020 | -$95.32M | – |
| FY2019 | Dec 31, 2019 | -$87.38M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$10.17M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.11M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.96M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.60M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.39M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.93M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.55M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.68M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.61M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.17M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.42M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$30.76M | – |
| Q4 FY2021 | Dec 31, 2021 | -$46.60M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.81M | – |
| Q2 FY2021 | Jun 30, 2021 | -$28.79M | – |
| Q1 FY2021 | Mar 31, 2021 | -$28.07M | – |
| Q4 FY2020 | Dec 31, 2020 | -$28.75M | – |
| Q3 FY2020 | Sep 30, 2020 | -$25.62M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.06M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.90M | – |
See a number that looks wrong?